ES2036560T3 - Un metodo para preparar una composicion sinergicamente activa para el tratamiento de hipertension. - Google Patents

Un metodo para preparar una composicion sinergicamente activa para el tratamiento de hipertension.

Info

Publication number
ES2036560T3
ES2036560T3 ES198787116236T ES87116236T ES2036560T3 ES 2036560 T3 ES2036560 T3 ES 2036560T3 ES 198787116236 T ES198787116236 T ES 198787116236T ES 87116236 T ES87116236 T ES 87116236T ES 2036560 T3 ES2036560 T3 ES 2036560T3
Authority
ES
Spain
Prior art keywords
hypertension
preparing
treatment
active composition
synergically
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES198787116236T
Other languages
English (en)
Inventor
Richard C. Dage
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aventis Pharmaceuticals Inc
Original Assignee
Merrell Dow Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharmaceuticals Inc filed Critical Merrell Dow Pharmaceuticals Inc
Application granted granted Critical
Publication of ES2036560T3 publication Critical patent/ES2036560T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

ESTA INVENCION SE REFIERE AL REFORZAMIENTO SINERGISTICO DE ALGUNOS AGENTES ANTIHIPERTENSORES POR USO EN COMBINACION CON ALGUNOS AGENTES CARDIOTONICOS. MAS ESPECIFICAMENTE ESTA INVENCION SE REFIERE AL REFORZAMIENTO DEL EFECTO REDUCTOR DE LA PRESION SANGUINEA CONSEGUIDO CON ANTAGONISTAS DE ALFA-ADRENOCEPTORES, POR LA ADMINISTRACION CONJUNTA DE AGENTES CARDIOTONICOS QUE POSEEN LA CAPACIDAD DE INHIBIR ESPECIFICAMENTE AMP-FOSFODIESTERASA CICLICA.
ES198787116236T 1986-11-05 1987-11-04 Un metodo para preparar una composicion sinergicamente activa para el tratamiento de hipertension. Expired - Lifetime ES2036560T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US92778586A 1986-11-05 1986-11-05

Publications (1)

Publication Number Publication Date
ES2036560T3 true ES2036560T3 (es) 1993-06-01

Family

ID=25455252

Family Applications (1)

Application Number Title Priority Date Filing Date
ES198787116236T Expired - Lifetime ES2036560T3 (es) 1986-11-05 1987-11-04 Un metodo para preparar una composicion sinergicamente activa para el tratamiento de hipertension.

Country Status (11)

Country Link
EP (1) EP0268146B1 (es)
JP (1) JP2612175B2 (es)
KR (1) KR950013758B1 (es)
AT (1) ATE59781T1 (es)
DE (1) DE3767287D1 (es)
DK (1) DK167209B1 (es)
ES (1) ES2036560T3 (es)
GR (1) GR3001375T3 (es)
IE (1) IE59905B1 (es)
PH (1) PH23818A (es)
ZA (1) ZA878182B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT996447E (pt) * 1997-05-19 2006-12-29 Zonagen Inc Terapia combinada para moldular a resposta sexual humana
HUP0100705A3 (en) * 1997-12-16 2001-12-28 Pfizer Prod Inc Combination effective for the treatment of impotence
DE102004011512B4 (de) 2004-03-08 2022-01-13 Boehringer Ingelheim Vetmedica Gmbh Pharmazeutische Zubereitung enthaltend Pimobendan
EP1579862A1 (en) 2004-03-25 2005-09-28 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the reduction of heart size in mammals suffering from heart failure
US8980894B2 (en) 2004-03-25 2015-03-17 Boehringer Ingelheim Vetmedica Gmbh Use of PDE III inhibitors for the treatment of asymptomatic (occult) heart failure
EP1920785A1 (en) 2006-11-07 2008-05-14 Boehringer Ingelheim Vetmedica Gmbh Liquid preparation comprising a complex of pimobendan and cyclodextrin
EP3167876B1 (en) 2012-03-15 2021-09-08 Boehringer Ingelheim Vetmedica GmbH Pharmaceutical tablet formulation for the veterinary medical sector, method of production and use thereof
US20130274245A1 (en) * 2012-04-11 2013-10-17 Jan BLUMENSTEIN Composition For Prevention of Vasoactivity in the Treatment of Blood Loss and Anemia
CN113181110A (zh) 2013-07-19 2021-07-30 勃林格殷格翰动物保健有限公司 含有防腐的醚化的环糊精衍生物的液体水性药物组合物
BR112016011111B1 (pt) 2013-12-04 2022-11-16 Boehringer Ingelheim Vetmedica Gmbh Composições farmacêuticas aprimoradas de pimobendan
US10537570B2 (en) 2016-04-06 2020-01-21 Boehringer Ingelheim Vetmedica Gmbh Use of pimobendan for the reduction of heart size and/or the delay of onset of clinical symptoms in patients with asymptomatic heart failure due to mitral valve disease

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4130647A (en) * 1977-07-08 1978-12-19 Pfizer Inc. Methods for treating congestive heart failure and ischemic heart disease
US4601897A (en) * 1985-11-06 1986-07-22 Pfizer Inc. Prazosin-pirbuterol combination for bronchodilation

Also Published As

Publication number Publication date
JP2612175B2 (ja) 1997-05-21
DE3767287D1 (de) 1991-02-14
IE872975L (en) 1988-05-05
DK167209B1 (da) 1993-09-20
DK578887D0 (da) 1987-11-04
EP0268146B1 (en) 1991-01-09
GR3001375T3 (en) 1992-09-11
JPS63132837A (ja) 1988-06-04
KR880005934A (ko) 1988-07-21
KR950013758B1 (ko) 1995-11-15
EP0268146A1 (en) 1988-05-25
DK578887A (da) 1988-05-06
PH23818A (en) 1989-11-23
ATE59781T1 (de) 1991-01-15
IE59905B1 (en) 1994-04-20
ZA878182B (en) 1988-05-02

Similar Documents

Publication Publication Date Title
BR0012136A (pt) Inibidores de reabsorção de norepinefrina altamente seletivos e métodos de uso dos mesmos
PT740650E (pt) Co-farmacos como um metodo de administracao controlada de farmacos
DK0563093T3 (da) Præparat anvendt som terapeutisk middel mod kroniske virale hepatitissygdomme
ES2036560T3 (es) Un metodo para preparar una composicion sinergicamente activa para el tratamiento de hipertension.
IS3284A7 (is) Aðferð við framleiðslu á N1-súbstitúeruðum bensimidasólafleiðum til að nota við lækningar
DK154208C (da) Analogifremgangsmaade til fremstilling af p-substituerede 3-fenoxy-1-alkylaminopropanoler eller terapeutisk acceptable salte deraf
DE60322102D1 (de) Transdermales buprenorphin-dosierschema zwecks schmerzstillung
ES2084339T3 (es) Tetrahidropiridinas e hidroxipiperidinas sustituidas utiles como agentes para el sistema nervioso central.
ES2032905T3 (es) Sistema terapeutico transcutaneo.
ES2038650T3 (es) Procedimiento para preparar una composicion farmaceutica que comprende 3'-desoxitimidin-2'-eno-(3'-desoxi-2',3'-dideshidrotimidina) para tratar pacientes infectados con retrovirus.
ATE78031T1 (de) Prostaglandin-derivate zur behandlung von glaucoma oder augenueberdruck.
ES2037742T3 (es) Procedimiento de obtencion de una composicion para administracion intravenosa.
NO164904C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive griseolsyrederivater.
AU587054B2 (en) Novel pharmaceutical compositions intended to the treatment of neuropathies and insuring the nervous regeneration
ES2185153T3 (es) Uso de mefloquina(+) para el tratamiento de la malaria.
ATE334590T1 (de) Anti-arrhythmische zusammensetzungen und behandlungsverfahren
KR910009270A (ko) 15-케토-프로스타글란딘 화합물을 이용한 심기능장애의 치료방법
DK0378146T3 (da) Polyamin-derivater som antineoplastiske midler
HUP9903679A2 (hu) Olanzapin alkalmazása bipoláris zavar kezelésére szolgáló gyógyszerkészítmények előállítására
ES2181407T3 (es) Glucocorticoides para tratar la glomerulonefritis.
PT1059845E (pt) Composicao fungicida compreendendo uma benzoilfenilureia
DK0669826T3 (da) (-)-Metrifonatholdigt lægemiddel
AR018471A1 (es) Metodo para el tratamiento de la perdida del cabello el cual comprende administrar una composicion que comprende un compuesto el cual no afectaal corazon
AR005724A1 (es) Derivados de ureido biologicamente activos utiles en el tratamiento de esclerosis multiple
DK277387D0 (da) Terapeutisk topikal sammensaetning mod en hyperprolifererende epithelsygdom

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 268146

Country of ref document: ES